Highlights

  • Abivax shares surged 21% following reports of potential acquisition interest from Eli Lilly.
  • Positive Phase 3 trial results for ulcerative colitis drug obefazimod likely influenced investor activity.
  • Market speculation continues despite Eli Lilly declining to comment on business development.

France-based biotech Abivax (NASDAQ:ABVX) saw its share price climb nearly 21% on December 22, 2025, following media reports that Eli Lilly, a major US pharmaceutical company, could be considering an acquisition. According to French publication La Lettre, Eli Lilly representatives met with French Treasury officials to discuss regulatory requirements for acquiring Abivax.

This surge marked the second significant rally in December after similar rumors circulated on December 10. On that occasion, shares rose sharply even though Eli Lilly had stated it would not comment on “business development activity.”

Clinical Trial Results Attract Attention
The attention from Eli Lilly coincides with Abivax’s positive Phase 3 results for obefazimod, a drug for ulcerative colitis. These results appear to have played a role in sparking investor interest, as acquisitions in the pharmaceutical sector often follow promising clinical trial outcomes.

Eli Lilly’s ongoing strategy includes acquiring companies with notable assets, exemplified by its recent acquisition of Adverum Biotechnologies, which expanded its gene therapy portfolio in ophthalmology.

Market Response and Speculation
Despite the price jump, analysts note that persistent rumors may influence the premium at which Abivax could be sold. Investors continue to monitor developments closely, but the market remains cautious as no official confirmation has been provided by either company.

Share Price Snapshot
The stock closed at USD 138.72, up USD 23.78. It traded between USD 130.14 and USD 139.62, with an after-hours price of USD 139.50.